Victory Capital Management
HBIO icon

Victory Capital Management’s Harvard Bioscience HBIO Stock Holding History

Victory Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,805
Closed -$96.6K – 2515
2023
Q4 		$96.6K Buy
1,805
+96
+6% +$4.33K ﹤0.01% 2348
2023
Q3 		$73.5K Hold
1,709
– – ﹤0.01% 2344
2023
Q2 		$93.8K Hold
1,709
– – ﹤0.01% 2321
2023
Q1 		$71.8K Hold
1,709
– – ﹤0.01% 2402
2022
Q4 		$47.3K Buy
1,709
+426
+33% +$10.5K ﹤0.01% 2458
2022
Q3 		$33K Buy
1,283
+54
+4% +$1.79K ﹤0.01% 2596
2022
Q2 		$44K Sell
1,229
-40
-3% -$1.8K ﹤0.01% 2560
2022
Q1 		$79K Sell
1,269
-22
-2% -$1.3K ﹤0.01% 2546
2021
Q4 		$91K Sell
1,291
-35
-3% -$2.49K ﹤0.01% 2587
2021
Q3 		$93K Buy
1,326
+15
+1% +$1.19K ﹤0.01% 2628
2021
Q2 		$109K Sell
1,311
-1,289
-50% -$91.2K ﹤0.01% 2590
2021
Q1 		$142K Buy
+2,600
New +$126K ﹤0.01% 2562
2020
Q2 		– Sell
-1,226
Closed -$28K – 2832
2020
Q1 		$28K Buy
+1,226
New +$33.2K ﹤0.01% 2977
2019
Q4 		– Sell
-461
Closed -$14K – 2902
2019
Q3 		$14K Buy
+461
New +$11.5K ﹤0.01% 3153

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Victory Capital Management's HBIO Position: Q1 2024 in Review

Victory Capital Management sold out of Harvard Bioscience (HBIO) in Q1 2024, closing a stake of 1,805 shares — an estimated $96.6K sold.

Victory Capital Management first reported a position in HBIO in Q3 2019 and held it in 14 quarters. The position peaked at $142K in Q1 2021. 89 funds tracked by Wall St. Rank hold HBIO as of Q1 2024.

  • Victory Capital Management reported no remaining Harvard Bioscience position as of Q1 2024 after selling out during the quarter.
  • Victory Capital Management sold 1,805 Harvard Bioscience shares in Q1 2024, an estimated $96.6K.
  • Victory Capital Management first reported a position in Harvard Bioscience in Q3 2019 and held it in 14 quarters.
  • Victory Capital Management's Harvard Bioscience position peaked at $142K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2024.

Based on Victory Capital Management's 13F filing for Q1 2024, filed 3 May 2024.